3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Interleukin-15
×
Gastrointestinal
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled